Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a local anesthetic stop shingles pain from becoming chronic?

NCT ID NCT06882525

Symptom relief Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether injecting lidocaine under the skin at the shingles rash site can reduce pain and help prevent post-herpetic neuralgia, a long-lasting nerve pain that can follow shingles. Adults with acute shingles pain or established post-herpetic neuralgia will receive three injections, one week apart. Researchers will measure pain scores before and after each injection to see if the treatment provides relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
subcutaneous lidocaine injections
What this could lead to
If it works, this could offer a simple, low-cost way to ease shingles pain and lower the chance of developing long-term nerve pain after shingles.
What could go wrong
This is an early, unrandomized study, so results may not be conclusive. Lidocaine can cause allergic reactions, and the injections may not prevent post-herpetic neuralgia in everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Apr 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients over the age of 18 * with acute HZ pain (rash duration \< 30 days * pain due to PHN (rash duration \> 3 months), Exclusion Criteria: patients on anticoagulants or have coagulation disorders, patients with psychomotor disorders patients with uncontrolled diabetes patients with bacterial infection or infectious discharge in the affected dermatomal region patients allergic to lidocaine patients with lesions in the facial or genital regions pregnant or breastfeeding patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

herpes zoster Neuralgia, Postherpetic postherpetic neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster Neuralgia, postherpetic

Contacts and locations

Locations

  • Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya/ANKARA

    Ankara, Cankaya, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.